Pharvaris (NASDAQ:PHVS) Cut to “Sell” at Wall Street Zen

Pharvaris (NASDAQ:PHVS) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Sunday.

Other equities analysts have also issued reports about the stock. Royal Bank Of Canada assumed coverage on shares of Pharvaris in a research note on Monday, March 9th. They issued an “outperform” rating and a $52.00 price target on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pharvaris in a research note on Thursday, January 22nd. Finally, HC Wainwright restated a “buy” rating and issued a $60.00 price objective on shares of Pharvaris in a research report on Tuesday, March 3rd. Ten analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Pharvaris currently has a consensus rating of “Moderate Buy” and a consensus price target of $41.70.

Pharvaris Price Performance

PHVS opened at $28.56 on Friday. The firm has a fifty day moving average price of $27.05 and a 200 day moving average price of $25.43. The stock has a market cap of $1.55 billion, a P/E ratio of -8.47 and a beta of -2.58. Pharvaris has a 1 year low of $11.51 and a 1 year high of $29.85.

Pharvaris (NASDAQ:PHVS) last posted its earnings results on Monday, April 6th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by ($0.14). Equities analysts expect that Pharvaris will post -2.71 EPS for the current year.

Institutional Trading of Pharvaris

Several large investors have recently added to or reduced their stakes in PHVS. General Atlantic L.P. raised its position in shares of Pharvaris by 6.6% in the 3rd quarter. General Atlantic L.P. now owns 8,031,252 shares of the company’s stock valued at $200,380,000 after purchasing an additional 500,000 shares in the last quarter. Foresite Capital Management IV LLC grew its stake in Pharvaris by 8.3% during the 3rd quarter. Foresite Capital Management IV LLC now owns 4,778,581 shares of the company’s stock worth $119,226,000 after buying an additional 368,000 shares during the last quarter. venBio Partners LLC grew its position in shares of Pharvaris by 8.2% during the third quarter. venBio Partners LLC now owns 4,639,304 shares of the company’s stock worth $115,751,000 after acquiring an additional 350,000 shares during the last quarter. Deerfield Management Company L.P. grew its holdings in Pharvaris by 21.1% in the 3rd quarter. Deerfield Management Company L.P. now owns 2,442,464 shares of the company’s stock worth $60,939,000 after buying an additional 425,000 shares in the last quarter. Finally, Commodore Capital LP increased its stake in Pharvaris by 26.5% during the 3rd quarter. Commodore Capital LP now owns 2,418,476 shares of the company’s stock valued at $60,341,000 after buying an additional 507,043 shares during the period.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.